Teijaro Lab
@Teijaro_Lab
Followers
386
Following
77
Media
10
Statuses
51
Chronic viral infections, Chemical Immunology, and immuno-oncology @ScrippsResearch
La Jolla, San Diego
Joined March 2018
Dysregulated ISG15 production and signaling during persistent LCMV infection drives lethal immune pathology, representing a therapeutic target during severe viral infections with pulmonary manifestations @J_Immunol @NamirShaabani @Teijaro_Lab
https://t.co/dl23wsOoDr
0
4
14
Congrats to everyone involved. @andyjminn, @EJohnWherry, @divijmathew, @zakjerry1 and @Isa57569543. Two great complimentary studies that hopefully will catalyze better treatments for patients in need soon! 👏
In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunotherapy enhances cancer patient response. Learn more ⬇️ 📄: https://t.co/Ecu5mWIFUV 📄: https://t.co/7zbvlPlqXS
#SciencePerspective: https://t.co/vlIVqzBLqK
1
0
15
JAK inhibitors enhance anti–PD-1 immunotherapy by modulating T cell exhaustion and inflammatory signaling, as shown in preclinical models and clinical trials for non-small cell lung cancer and Hodgkin lymphoma. https://t.co/7OSh9UAGDp
https://t.co/LkEILkU1VY
#NBThighlight
science.org
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after...
0
23
81
Proud of my two post-docs on their Science paper demonstrating JAK inhibitors can promote better anti-tumor responses in combination with checkpoint immunotherapy. Well done Jerry and Isa as well as all the authors! Special thanks to Dr. Veronika Bachanova for running the trial!
A new @ScienceMagazine study led by Prof. John Teijaro, PhD, found that combining ruxolitinib, an approved drug, with checkpoint inhibitors supercharged T-cell responses. This could transform #cancer treatment, especially for tough-to-treat cancers. More: https://t.co/rVI71IunpT
3
2
25
https://t.co/1JqFpiCjEp Pleased to see this one in print. What a journey with the parker lab @_chrisgparker_! Great example of merging chemical biology and immunology to generate an exciting tool to probe the immune response. Congrats to everyone involved and all the hard work!!
1
3
21
Excited to share the final version in @nchembio. Lots more mechanistic insights & characterization, including our inhibitors disrupt PPIs with mTOR components & induce lysosomal degradation of SLC15A4, & more. A promising target for autoimmune conditions.
nature.com
Nature Chemical Biology - Integrated chemoproteomic development of selective small-molecule SLC15A4 inhibitors and their functional characterization establish SLC15A4 as a druggable target for...
6
24
159
Humbled to be a part of this newest venture with great colleagues Ben Cravatt, Chris Parker and Stuart Schreiber. Looking forward to what lies ahead!
Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and a multi-year collaboration with Genentech. https://t.co/0KZmj2MnQS
1
1
19
Excited to share work with our lab and Parker lab @_chrisgparker_ on the development and characterization of the first Slc15a4 inhibitors. https://t.co/KJ2MOVrM5L
0
2
16
Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy
biorxiv.org
Unleashing anti-tumor T cell activity by checkpoint inhibition is effective in many cancer patients but clinical response rates remain limited. Myeloid derived suppressor cells erode antitumor...
0
0
3
Check out the review by @_chrisgparker_ from @scrippsresearch on the integration #phenotypic #screening and #chemoproteomics, in particular using chemoproteomic-enabled libraries to streamline the #drug #discovery process
0
5
15
Congratulations to @EOSaphire on being newly appointed as President and CEO @ljiresearch. A former graduate student and accomplished faculty member at Scripps Research, we wish her much success in her continued leadership in immunology and virology.
NEWS: Dr. Erica Ollmann Saphire appointed president and CEO of La Jolla Institute for Immunology https://t.co/5tzTwv5XqF
#SanDiego #LaJolla #immunology #health #biotech #biomedicine
1
6
43
COVID-19 vaccines: modes of immune activation and future challenges https://t.co/GK8EkBtK1P
3
157
387
Merry Christmas and Happy Holidays from all of us in the Teijaro Lab!
0
0
13
Great example of basic research at Scripps and the Calibr drug discovery engine coming together to advance medicines for human disease. Watch this space. Congrats to all involved!
STING attack on #cancer! In work by @Teijaro_Lab & Lairson Lab, Scripps Research scientists discover a drug that can activate the immune-boosting protein STING. Efficacy against #melanoma shows its potential as a future #anticancer therapy https://t.co/9HVGXuDL4r
@ScienceMagazine
0
0
7
Great day for the lab! Our collaborative work with Luke Larson's lab and Calibr came out today in Science! Congratulations to Vincent, Emily, Ying, and the whole team! We identified and characterized a novel, anti-tumor STING agonist, SR-717. Read it here: https://t.co/E9yH02iZrK
8
12
57
Great collaborative effort! #ScrippsResearch #IAVI #UCSD Find the paper here: https://t.co/XTvdvFL81M
0
2
11
Tour de force!
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
0
2
10
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
0
3
8
The latest story from our lab describing the detrimental effects of extracelluar ISG15 in the lungs during viral infection is on BioRxiv now! Congratulations to our postdoc Namir Shaabani, who is the first author! Check it out here: https://t.co/svLULSpxFt
1
4
28
Wendy L Havran, 1955-2020 | With heavy hearts, we mourn the sudden passing of a very dear friend on January 20, 2020 | An exceptional scientist | A mentor to all | A community leader | A warm generous personality | A grande dame always | @ScrippsResearch | #WeMissYouWendy
0
4
17